Latest Breaking News On - Marginal zone lymphoma - Page 1 : comparemela.com

Genmab A/S: Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide

United-states
Japan
Boston
Massachusetts
Chicago
Illinois
Denmark
Copenhagen
Køavn
Canada
American
America

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

02.06.2024 - Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of .

Japan
Canada
Copenhagen
Køavn
Denmark
United-states
America
Judith-klimovsky
Asia-pacific
Hematol-hemoter
Joshua-brody
Nasdaq

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Chicago
Illinois
United-states
Japan
Canada
Copenhagen
Køavn
Denmark
Boston
Massachusetts
America
American

Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024

Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Paris
France-general
France
Chicago
Illinois
United-states
American
Ashleyr-robinson
Jan-fagerberg
Guillaume-bayre
Weid-europe
Lifesci-advisors

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

Lori-leslie
Jamesk-mccloskey
Gloria-leslie
Peer-exchange
Research-programs
John-theurer-cancer-center
Hackensack-university-medical-center
Hackensack-university-medical
Associate-professor
Indolent-lymphoma
Lymphoma